AI 聊天
Loading data for STVN — first visit, this takes a few seconds.

Stevanato Group S.p.A.

STVN · NYSE · USD

21.70 -0.97 (-4.28%)

收盤價: Sep 18, 2026, 8:00 PM

21.81 +0.51%

盤後: 7:30 PM

市值
$5.93B
下次財報日期
Nov 5, 2026

Stevanato Group S.p.A.(STVN)股價、分析與資料

內在價值

估值模型屬於 Pro 功能。登入或升級後可查看完整分析。

查看方案 →

分析師預測

股票預測 →

目標價

$20,00 – $32,00

中位數 $25,00 · 15.21% 上漲空間

12個月目標價 · 12 位分析師

分析師共識: 購買

間隔:1D
正在載入K線和訊號…

財務表現

查看財務 →

正在載入...

最新財報

已通報較預期YoY 變更
營收$302.0Mn/a+7.84%
EPS$0,16+$0,01+23.08%

下次財報

開盤前。

估計 · 升級 →

查看財報詳情 →

指標

買價
21.75
市值
5.93B
淨利(ttm)
135M
0.75
0.56
38.75
25.63
P/B (ttm)
3.29
P/S (ttm)
4.84
財報日期
Nov 5, 2026
賣價
21.78
成交量
265,531
20 日平均成交量
381,737
開盤價
22.60
前收盤價
22.67
當日區間
21.61 - 23.25
52 週範圍
12.89 - 28.00
分析師
購買
目標價
25 (15.21%)
股利
$0.06 (0.28%)
除息日
Jun 11, 2026

關於 Stevanato Group S.p.A.

查看公司資料 →
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L. Medical Instruments & Supplies · Healthcare

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

類股 Healthcare
IPO 日期 Jul 16, 2021
員工 6,010
證券交易所 NYSE
股票代號 STVN